Jeonnam Biomedical Research Center Signs MOU for 'National Vaccine Commercialization'

[Asia Economy Honam Reporting Headquarters Reporter Yoon Jamin] The Jeonnam Bioindustry Promotion Institute Biopharmaceutical Research Center (Director Kwak Wonjae) announced on the 15th that it has signed a business agreement with the Catholic University Vaccine Bio Research Institute and the Korea Biopharmaceutical Association to succeed in the ‘National Vaccine Commercialization Support Project’ promoted by the Ministry of Food and Drug Safety and Jeonnam Province.

Through this agreement, the Biopharmaceutical Research Center, Catholic University, and the Korea Biopharmaceutical Association will mutually cooperate on establishing a laboratory for vaccine clinical trial specimen analysis, as well as information, technology, and personnel exchanges for vaccine immunogenicity evaluation tests.

Accordingly, systematic support will be provided for immunogenicity evaluation and quality inspection of clinical specimens of nationally essential vaccines under development in Korea, and the Hwasun Vaccine Industrial Complex, the only one in the country, is expected to play a pivotal role in the development and early commercialization of national essential vaccines.

Kwak Wonjae, director of the Biopharmaceutical Research Center, said, “This agreement enables information and technology exchange and personnel exchange for vaccine clinical specimen analysis, making rapid vaccine commercialization possible,” adding, “It will be an opportunity to expedite the establishment of the National Vaccine Commercialization Support Center, which will serve as a public control tower for vaccine development, including clinical specimen analysis, quality inspection, and commercialization support.”

Kang Jinhan, director of the Catholic University Vaccine Bio Research Institute, said, “Our institute has been specializing in pertussis vaccine research,” and added, “We will do our best to carry out the project based on our research achievements.”

Park Jungtae, vice president of the Korea Biopharmaceutical Association, emphasized, “The association and its member companies will continuously cooperate to rapidly commercialize vaccines and contribute to improving public health.”

Meanwhile, the Ministry of Food and Drug Safety and Jeonnam Province have been investing 21.3 billion KRW of national funds since last year until 2022 to establish the ‘National Vaccine Commercialization Support Center’ in the Hwasun Vaccine Industrial Complex, providing technology support and consulting throughout the entire cycle from vaccine research and development to approval for domestic pharmaceutical companies, aiming to lead rapid vaccine commercialization and overseas exports.

This content was produced with the assistance of AI translation services.